Sonelokimab + Placebo + Adalimumab
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Arthritis, Psoriatic
Conditions
Arthritis, Psoriatic
Trial Timeline
Dec 13, 2022 → Jan 15, 2024
NCT ID
NCT05640245About Sonelokimab + Placebo + Adalimumab
Sonelokimab + Placebo + Adalimumab is a phase 2 stage product being developed by MoonLake Immunotherapeutics for Arthritis, Psoriatic. The current trial status is completed. This product is registered under clinical trial identifier NCT05640245. Target conditions include Arthritis, Psoriatic.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05640245 | Phase 2 | Completed |
Competing Products
20 competing products in Arthritis, Psoriatic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tilmanocept | Navidea Biopharmaceuticals | Phase 1 | 25 |
| Tc99m tilmanocept | Navidea Biopharmaceuticals | Phase 2 | 44 |
| KPL-404 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Baricitinib + Methotrexate + Baricitinib Placebo + MTX Placebo + Folic Acid | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2828360 + Placebo | Eli Lilly | Phase 2 | 52 |
| Investigational Medical Product (IMP) administered in parent study | Eli Lilly | Phase 3 | 77 |
| Sonelokimab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Sonelokimab + Placebo + Risankizumab | MoonLake Immunotherapeutics | Phase 3 | 72 |
| Dose A VTX958 + Dose B VTX958 + Placebo | Ventyx Biosciences | Phase 2 | 47 |
| LY2127399 | Eli Lilly | Phase 3 | 77 |
| Ixekizumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Duloxetine + Sugar pill | Eli Lilly | Approved | 85 |
| Ixekizumab + Tirzepatide | Eli Lilly | Pre-clinical | 23 |
| Ixekizumab + Tirzepatide | Eli Lilly | Phase 3 | 77 |
| Baricitinib + TNF Inhibitor | Eli Lilly | Approved | 85 |
| Ixekizumab + Adalimumab | Eli Lilly | Approved | 85 |
| UBX0101 or placebo | Unity Biotechnology | Pre-clinical | 15 |
| UBX0101 | Unity Biotechnology | Phase 1 | 25 |